Compared to Estimates, Steris (STE) Q3 Earnings: A Look at Key Metrics

Zacks Zacks
Compared to Estimates, Steris (STE) Q3 Earnings: A Look at Key Metrics

For the quarter ended December 2025, Steris (STE) reported revenue of $1.5 billion, up 9.2% over the same period last year. EPS came in at $2.53, compared to $2.32 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $1.48 billion, representing a surprise of +1.08%. The company delivered an EPS surprise of -0.1%, with the consensus EPS estimate being $2.53.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Steris performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Healthcare: $1.06 billion versus the four-analyst average estimate of $1.05 billion. The reported number represents a year-over-year change of +9%. Revenues- Healthcare Products- Consumables: $387.1 million versus the four-analyst average estimate of $381.88 million. The reported number represents a year-over-year change of +8.1%. Revenues- Healthcare Products- Capital Equipment: $272.1 million versus the four-analyst average estimate of $278.71 million. The reported number represents a year-over-year change of +6.8%. Revenues- Healthcare Products- Service: $404.7 million versus the four-analyst average estimate of $391.52 million. The reported number represents a year-over-year change of +11.5%. Revenues- Life Sciences: $145.8 million versus $148.25 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +6.9% change. Revenues- Applied Sterilization Technologies (AST): $286.6 million compared to the $278.6 million average estimate based on four analysts. The reported number represents a change of +11% year over year. Revenues- Life Sciences- Service: $36.5 million versus the three-analyst average estimate of $39.26 million. The reported number represents a year-over-year change of -0.4%. Revenues- Life Sciences- Capital Equipment: $33.3 million compared to the $36.67 million average estimate based on three analysts. The reported number represents a change of +7.2% year over year. Revenues- Life Sciences- Consumables: $75.9 million compared to the $71.77 million average estimate based on three analysts. The reported number represents a change of +10.5% year over year. Operating income / (loss)- Healthcare: $258.1 million versus the three-analyst average estimate of $257.71 million. Operating income / (loss)- Corporate and Other: $-106 million versus the three-analyst average estimate of $-103.36 million. Operating income / (loss)- Applied Sterilization Technologies (AST): $129.2 million versus $125.53 million estimated by three analysts on average.

View all Key Company Metrics for Steris here>>>

Shares of Steris have returned +0.6% over the past month versus the Zacks S&P 500 composite's +0.9% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Free Report: Profiting from the 2nd Wave of AI Explosion

The next phase of the AI explosion is poised to create significant wealth for investors, especially those who get in early. It will add literally trillion of dollars to the economy and revolutionize nearly every part of our lives.

Investors who bought shares like Nvidia at the right time have had a shot at huge gains.

But the rocket ride in the "first wave" of AI stocks may soon come to an end. The sharp upward trajectory of these stocks will begin to level off, leaving exponential growth to a new wave of cutting-edge companies.

Zacks'  AI Boom 2.0: The Second Wave report reveals 4 under-the-radar companies that may soon be shining stars of AI’s next leap forward.

Access AI Boom 2.0 now, absolutely free >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report


 
STERIS plc (STE): Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

Other news